...
首页> 外文期刊>BMC Cancer >A systematic review of clinic and community intervention to increase fecal testing for colorectal cancer in rural and low-income populations in the United States – How, what and when?
【24h】

A systematic review of clinic and community intervention to increase fecal testing for colorectal cancer in rural and low-income populations in the United States – How, what and when?

机译:对临床和社区干预进行系统评价,以增加美国农村和低收入人群大肠癌粪便检测的方法–方式,时间和时间?

获取原文
           

摘要

Interventions to improve fecal testing for colorectal cancer (CRC) exist, but are not yet routine practice. We conducted this systematic review to determine how implementation strategies and contextual factors influenced the uptake of interventions to increase Fecal Immunochemical Tests (FIT) and Fecal Occult Blood Testing (FOBT) for CRC in rural and low-income populations in the United States. We searched Medline and the Cochrane Library from January 1998 through July 2016, and Scopus and clinicaltrials.gov through March 2015, for original articles of interventions to increase fecal testing for CRC. Two reviewers independently screened abstracts, reviewed full-text articles, extracted data and performed quality assessments. A qualitative synthesis described the relationship between changes in fecal testing rates for CRC, intervention components, implementation strategies, and contextual factors. A technical expert panel of primary care professionals, health system leaders, and academicians guided this work. Of 4218 citations initially identified, 27 unique studies reported in 29 publications met inclusion criteria. Studies were conducted in primary care (n?=?20, 74.1%), community (n?=?5, 18.5%), or both (n?=?2, 7.4%) settings. All studies (n?=?27, 100.0%) described multicomponent interventions. In clinic based studies, components that occurred most frequently among the highly effective/effective study arms were provision of kits by direct mail, use of a pre-addressed stamped envelope, client reminders, and provider ordered in-clinic distribution. Interventions were delivered by clinic staff/community members (n?=?10, 37.0%), research staff (n?=?6, 22.2%), both (n?=?10, 37.0%), or it was unclear (n?=?1, 3.7%). Over half of the studies lacked information on training or monitoring intervention fidelity (n?=?15, 55.6%). Studies to improve FIT/FOBT in rural and low-income populations utilized multicomponent interventions. The provision of kits through the mail, use of pre-addressed stamped envelopes, client reminders and in-clinic distribution appeared most frequently in the highly effective/effective clinic-based study arms. Few studies described contextual factors or implementation strategies. More robust application of guidelines to support reporting on methods to select, adapt and implement interventions can help end users determine not just which interventions work to improve CRC screening, but which interventions would work best in their setting given specific patient populations, clinical settings, and community characteristics. In accordance with PRISMA guidelines, our systematic review protocol was registered with PROSPERO, the international prospective register of systematic reviews, on April 16, 2015 (registration number CRD42015019557 ).
机译:存在用于改善大肠癌(CRC)的粪便测试的干预措施,但是尚无常规实践。我们进行了这项系统的审查,以确定在美国农村和低收入人群中,实施策略和背景因素如何影响干预措施的采用,以增加针对CRC的粪便免疫化学测试(FIT)和粪便隐血测试(FOBT)。我们从1998年1月至2016年7月搜索Medline和Cochrane图书馆,从2015年3月搜索Scopus和Clinicaltrials.gov,以寻找增加CRC粪便检测的干预措施原始文章。两名审稿人独立筛选摘要,审阅全文,提取数据并进行质量评估。定性综合描述了CRC的粪便检测率变化,干预成分,实施策略和背景因素之间的关系。由初级保健专业人员,卫生系统负责人和院士组成的技术专家小组指导了这项工作。在最初确定的4218篇引用文献中,有29篇出版物报道的27篇独特研究符合纳入标准。研究是在初级保健(n = 20、74.1%),社区(n = 5、18.5%)或两者(n == 2、7.4%)中进行的。所有研究(n = 27,100.0%)都描述了多因素干预。在基于临床的研究中,在高效研究组中发生频率最高的部分是通过直接邮寄提供试剂盒,使用预先贴有地址的邮票信封,客户提醒以及提供者订购的诊所内分发。干预是由诊所工作人员/社区成员(n = 10,37.0%),研究人员(n = 6、22.2%)(n = 10、37.0%)还是不清楚的( n≥1,3.7%)。超过一半的研究缺乏有关训练或监测干预忠诚度的信息(n = 15,55.6%)。在农村和低收入人群中提高FIT / FOBT的研究利用了多成分干预措施。在基于临床的高效研究机构中,通过邮件提供工具包,使用预先贴有邮票的信封,客户提醒和诊所内分发最为常见。很少有研究描述情境因素或实施策略。指南的更强大应用以支持有关选择,调整和实施干预措施的方法的报告,不仅可以帮助最终用户确定哪些干预措施可以改善CRC筛查,还可以确定哪种干预措施在给定特定的患者群体,临床环境和特定条件下效果最佳社区特征。根据PRISMA指南,我们的系统评价规程已于2015年4月16日在国际前瞻性系统评价寄存器PROSPERO中注册(注册号CRD42015019557)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号